A Diverse Panel of Clinical Acinetobacter baumannii for Research and Development
Madeline R. Galac, Erik Snesrud, François Lebreton, Jason Stam, Michael Julius, Ana Ong, Rosslyn Maybank, Anthony R. Jones, Yoon I. Kwak, Kate Hinkle, Paige Waterman, Emil Lesho, Jason W. Bennett, Patrick McGann
Abstract
Over the past two decades, Acinetobacter baumannii has emerged as a leading cause of nosocomial infections worldwide. Of particular concern are panresistant strains, leading the World Health Organization (WHO) to designate carbapenem-resistant A. baumannii as a priority 1 (critical) pathogen for research and development of new antibiotics. A key component in supporting this effort is accessibility to diverse and clinically relevant strains for testing. Here, we describe a panel of 100 diverse A. baumannii strains for use in this endeavor.